NextGen HIV prevention: New possibilities and questions

The Lancet

Volumn 387, Issue 10023, 2016, Pages 1036-1038

  Mayer, Kenneth H ^a,b  

^a FENWAY INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPIVIRINE; EMTRICITABINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAYED RELEASE FORMULATION;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEN WHO HAVE SEX WITH MEN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VAGINA RING; VIRUS TRANSMISSION; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; FEMALE; HIV INFECTIONS; MALE; MALE HOMOSEXUALITY; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES;

ANTI-HIV AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PRE-EXPOSURE PROPHYLAXIS;

EID: 84961197828     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00655-3     Document Type: Note

References (17)

1. MS Cohen, YQ Chen, M McCauley et al. Prevention of HIV-1 infection with early antiretroviral therapy N Engl J Med 365 2011 493 505
2. KH Mayer, G Ramjee The current status of the use of oral medication to prevent HIV transmission Curr Opin HIV AIDS 10 2015 226 232
3. L Van Damme, A Corneli, K Ahmed et al. Preexposure prophylaxis for HIV infection among African women N Engl J Med 367 2012 411 422
4. JM Marrazzo, G Ramjee, BA Richardson OICE Study Team Tenofovir-based preexposure prophylaxis for HIV infection among African women N Engl J Med 372 2015 509 518
5. Rees H, Delany-Moretlwe SA, Lombard C, et al. FACTS 001 phase III trial of pericoita tenofovir 1% gel for HIV prevention in women. 2015 Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; Feb 23-26, 2015. 26LB.
6. Beaten JM, Palanee-Phillips T, Brown ER, et al. A phase III trial of the dapivirine vaginal ring for HIV-1 prevention in women. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 109LB.
7. Nel A, Kapiga S, Bekker L, Devlin B, Borremans M, Rosenberg Z. Safety and efficacy of dapivirine vaginal ring for HIV-1 prevention in African women. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 110LB.
8. RM Grant, JR Lama, PL Anderson for the iPrEx Study Team Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2010 2587 2599
9. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. 2015 Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; Feb 23-26, 2015. 22LB.
10. DJ Murphy, P Boyd, CF McCoy et al. Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device J Control Release 226 2016 138 147
11. Gulick R, Wilkin TJ, Chen Y, et al. HPTN 069/ACTG 5305: phase II study of maraviroc-based regimens for HIV PrEP in MSM. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 103.
12. Cranston R, Lama J, Richardson BA, et al. MTN-017: rectal phase 2 extended safety and acceptability study of 1% tenofovir gel. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 108LB.
13. Markowitz M, Frank I, Grant R, et al. ÉCLAIR: phase 2A safety and PK study of cabotegravir LA in HIV-uninfected men. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 106.
14. Mascola JR. Harnessing antibodies for HIV-1 prevention and treatment. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 15.
15. Mayer KH, Seaton K, Huang Y, et al. Clinical safety and pharmacokinetics of VRC01, a broadly neutralizing monoclonal antibody. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; Feb 22-25, 2016. 90.
16. AMP Antibody Mediated Prevention Study HIV Prevention Trials Network, HIV Vaccine Trials Network http://www.ampstudy.org/ 2016 (accessed March 1, 2016).
17. J Sugarman Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials Curr Opin HIV AIDS 11 2016 109 115